EA202092109A1 - КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC - Google Patents

КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC

Info

Publication number
EA202092109A1
EA202092109A1 EA202092109A EA202092109A EA202092109A1 EA 202092109 A1 EA202092109 A1 EA 202092109A1 EA 202092109 A EA202092109 A EA 202092109A EA 202092109 A EA202092109 A EA 202092109A EA 202092109 A1 EA202092109 A1 EA 202092109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
sgc stimulator
present
sgc
fluorobenzyl
Prior art date
Application number
EA202092109A
Other languages
English (en)
Inventor
Кваме В. Нти-Аддае
Лина Кумари Прасад
Томас Сторц
Original Assignee
Сайклерион Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклерион Терапьютикс, Инк. filed Critical Сайклерион Терапьютикс, Инк.
Publication of EA202092109A1 publication Critical patent/EA202092109A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к кристаллическим формам 8-(2-фторбензил)-6-(3-(трифторметил)-1H-1,2,4-триазол-5-ил)имидазо[1,2-а]пиразина, которые применимы в качестве стимулятора растворимой гуанилатциклазы (sGC). Настоящее изобретение также представляет фармацевтически приемлемые композиции, содержащие кристаллические формы, и способы применения указанных композиций для лечения различных нарушений.
EA202092109A 2018-03-07 2019-03-07 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC EA202092109A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
EA202092109A1 true EA202092109A1 (ru) 2021-03-04

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092109A EA202092109A1 (ru) 2018-03-07 2019-03-07 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC

Country Status (20)

Country Link
US (2) US11466015B2 (ru)
EP (1) EP3762389B1 (ru)
JP (1) JP7423539B2 (ru)
KR (1) KR20200128708A (ru)
CN (1) CN111836812A (ru)
AU (1) AU2019231724B2 (ru)
BR (1) BR112020018212A2 (ru)
CA (1) CA3092683A1 (ru)
CL (5) CL2020002284A1 (ru)
CO (1) CO2020012493A2 (ru)
CR (1) CR20200458A (ru)
EA (1) EA202092109A1 (ru)
IL (1) IL276853A (ru)
MA (1) MA54638A (ru)
MX (5) MX2023004858A (ru)
PE (1) PE20210124A1 (ru)
PH (1) PH12020551394A1 (ru)
SG (1) SG11202008641WA (ru)
TW (1) TWI823903B (ru)
WO (1) WO2019173551A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100092QA (en) * 2018-07-11 2021-02-25 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
WO2024131850A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK1095016T3 (da) 1998-07-08 2006-03-13 Sanofi Aventis Deutschland Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP2197551B1 (en) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2564503T3 (es) 2010-05-27 2016-03-23 Merck Sharp & Dohme Corp. Activadores de la guanilato-ciclasa soluble
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
WO2016087342A1 (de) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
DK3507291T3 (da) 2016-09-02 2021-08-30 Cyclerion Therapeutics Inc Kondenserede bicykliske sgc-stimulatorer

Also Published As

Publication number Publication date
MA54638A (fr) 2021-11-10
MX2023004855A (es) 2023-11-24
JP2021515015A (ja) 2021-06-17
EP3762389B1 (en) 2024-02-28
BR112020018212A2 (pt) 2020-12-29
CL2020002284A1 (es) 2020-11-27
US20230095799A1 (en) 2023-03-30
CA3092683A1 (en) 2019-09-12
MX2023004856A (es) 2023-11-24
TW201940487A (zh) 2019-10-16
TWI823903B (zh) 2023-12-01
CO2020012493A2 (es) 2020-10-30
WO2019173551A1 (en) 2019-09-12
AU2019231724A1 (en) 2020-10-08
CN111836812A (zh) 2020-10-27
WO2019173551A8 (en) 2020-06-11
CR20200458A (es) 2020-11-09
PH12020551394A1 (en) 2021-11-22
JP7423539B2 (ja) 2024-01-29
CL2021003530A1 (es) 2022-08-19
AU2019231724B2 (en) 2024-06-27
MX2023004857A (es) 2023-11-24
KR20200128708A (ko) 2020-11-16
CL2021000301A1 (es) 2021-06-18
SG11202008641WA (en) 2020-10-29
US11466015B2 (en) 2022-10-11
MX2023004858A (es) 2023-11-24
MX2020009183A (es) 2020-10-08
IL276853A (en) 2020-10-29
CL2021003536A1 (es) 2022-08-19
EP3762389A1 (en) 2021-01-13
US20210115050A1 (en) 2021-04-22
PE20210124A1 (es) 2021-01-19
CL2021003531A1 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
EA202092109A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
MX2017009841A (es) 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
MX347632B (es) Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona.
EA202092108A1 (ru) Способ получения стимуляторов растворимой гуанилатциклазы
SE0100296D0 (sv) New compounds
SE0100297D0 (sv) New compounds
EA202090644A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3K
SE0303451D0 (sv) New compounds
SE0100295D0 (sv) New compounds
MX2023008755A (es) Cristales de sal.
EA201892684A1 (ru) [8-(фенилсульфонил)-3,8-диазабицикло[3.2.1]окт-3-ил](1н-1,2,3-триазол-4-ил)метаноны